clinical trial · NCT03568656
Study to Evaluate CCS1477 in Advanced Tumours
Metastatic Castration-Resistant Prostate CancerMetastatic Breast CancerNon-small Cell Lung CancerAdvanced Solid TumorsCCS1477Abiraterone acetateEnzalutamideDarolutamideOlaparibAtezolizumab
brief summary
A Phase 1/2a study to assess the safety, tolerability, PK and biological activity of CCS1477 in patients with metastatic castration resistant prostate cancer, metastatic breast cancer, non-small cell lung cancer or advanced solid tumours.
started
Jul 23, 2018
primary completion
Jul 6, 2025
completion
Jul 6, 2025
last updated
Aug 8, 2025
official title
An Open-label Phase I/IIa Study to Evaluate the Safety and Efficacy of CCS1477 as Monotherapy and in Combination, in Patients With Advanced Solid/Metastatic Tumours.
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol